Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
#WorldGI2020 good to see more 📊on #BRCA #DDR #HRR genes 🧬 in unselected #pancreascancer patients. Wide range of 4-21%. In this study of >500 European patients, #PANCSM 4-7% ē HRR-related aberrations. Other 🧬e.g. MUTYH notes as well. 📈towards better OS but not 🔢SS. #OncoAlert
#WORLDGI2020 great times to be talking about meaningful activity in 3️⃣rd line setting in patients ē
🟩FGFR🧬-fusion
#cholangiocarcinoma @curecc. Data @myESMO from @MDAndersonNews group. @WCGIC #OncoAlert #curecc
Advanced coming in subsets #PrecisionMedicine. “Target-rich” 🎯
🟩FGFR🧬-fusion
#cholangiocarcinoma @curecc. Data @myESMO from @MDAndersonNews group. @WCGIC #OncoAlert #curecc
Advanced coming in subsets #PrecisionMedicine. “Target-rich” 🎯
#WorldGI2020 and this👇🏾
More than just the ORR% in this setting, is how brisk, robust, & durable these tend to be ➕ECOG📈.
As noted @NEJM📝 & in our experience as well, have had stage-IV pts get secondary ‘curative’ resections‼️
🟩NTRK🧬Fusions
#OncoAlert #CRCSM #PANCSM #HPBCSM
More than just the ORR% in this setting, is how brisk, robust, & durable these tend to be ➕ECOG📈.
As noted @NEJM📝 & in our experience as well, have had stage-IV pts get secondary ‘curative’ resections‼️
🟩NTRK🧬Fusions
#OncoAlert #CRCSM #PANCSM #HPBCSM
#WORLDGI2020 Dr. @GABOUALFA presenting now on the options & landscape of options for our patients ē #hepatocellularcancer #HCC #HPBCSM.
From
🟩#Immuno-oncology (ICIs) to
🟦TKIs
🟥And now combinations (ATEZO/BEV; LEN/PEM)
💡Sequencing is going to a challenge but a good problem🔁.
From
🟩#Immuno-oncology (ICIs) to
🟦TKIs
🟥And now combinations (ATEZO/BEV; LEN/PEM)
💡Sequencing is going to a challenge but a good problem🔁.
#WORLDGI2020👇🏾
“Genomic fragmentation of metastatic #colorectalcancer”
Although I see fusions, I don’t see mention of #NTRK separately.
💡Even though rare, imp. to know that especially the MSI⬆️are enriched in NTRK🧬. Dramatic durable responses. Who to test? #CRCSM #oncoalert
“Genomic fragmentation of metastatic #colorectalcancer”
Although I see fusions, I don’t see mention of #NTRK separately.
💡Even though rare, imp. to know that especially the MSI⬆️are enriched in NTRK🧬. Dramatic durable responses. Who to test? #CRCSM #oncoalert
More on #ctDNA #liquidbiopsies
🦗👇🏾is the closest to one of the utilities of using 🩸🧬in clinic for metastatic #colorectalcancer patients.
❌rechallenge (or delay rechallenge till clones 🔴🟣🟡fade away) if known acquired mechanisms of resistance #WorldGI2020
#oncoalert #CRCSM
🦗👇🏾is the closest to one of the utilities of using 🩸🧬in clinic for metastatic #colorectalcancer patients.
❌rechallenge (or delay rechallenge till clones 🔴🟣🟡fade away) if known acquired mechanisms of resistance #WorldGI2020
#oncoalert #CRCSM
#WorldGI2020 🆕 Disappointing but important results of the RTOG1010 study.
🧬HER2⛔️➕ChemoXRT 🆚 ChemoXRT alone #ESOCSM
@ILSONDavid @sloan_kettering presenting #HappeningNow @myESMO @WCGIC
Numerically higher DFS but ❌ 🔢SS & no OS difference.
🧬? Other agents? #oncoalert
🧬HER2⛔️➕ChemoXRT 🆚 ChemoXRT alone #ESOCSM
@ILSONDavid @sloan_kettering presenting #HappeningNow @myESMO @WCGIC
Numerically higher DFS but ❌ 🔢SS & no OS difference.
🧬? Other agents? #oncoalert
#WorldGI2020 THIS👇🏾
🧬HER2⛔️
T-DXd
Trastuzumab deruxtecan
DS-8201
Moving from a negative study in advanced to a ➕study in metastatic setting. Interstitial Lung Disease (ILD) is a AE to watch out for.
🧬HER2⛔️
T-DXd
Trastuzumab deruxtecan
DS-8201
Moving from a negative study in advanced to a ➕study in metastatic setting. Interstitial Lung Disease (ILD) is a AE to watch out for.
#HappeningNow @myESMO
Dr. Harry Yoon @MayoClinic presenting on the serendipitous finding of the SEQUENCE.
🟢PD1⛔️➡️RAM/TAX📈
🔴RAM/TAX➡️PD1⛔️
👇🏾We were discussing this earlier last week @ASCO_pubs.
Exploratory. 19% prolonged benefit. 💡#WorldGI2020
Dr. Harry Yoon @MayoClinic presenting on the serendipitous finding of the SEQUENCE.
🟢PD1⛔️➡️RAM/TAX📈
🔴RAM/TAX➡️PD1⛔️
👇🏾We were discussing this earlier last week @ASCO_pubs.
Exploratory. 19% prolonged benefit. 💡#WorldGI2020
#WORLDGI2020 @myESMO
If the most important strides or 🔑 #clinicaltrials could be summed up in ☝🏽 slide, it is this👇🏾:
#Immunotherapy➕💊some TKI or VEGF⛔️
1️⃣Atezo➕BEV
2️⃣Len➕Pem
3️⃣Rego➕PD1/PDL1⛔️
4️⃣Cabo➕Nivo
What other combinations are you excited about❓#CRCSM #HPBCSM
If the most important strides or 🔑 #clinicaltrials could be summed up in ☝🏽 slide, it is this👇🏾:
#Immunotherapy➕💊some TKI or VEGF⛔️
1️⃣Atezo➕BEV
2️⃣Len➕Pem
3️⃣Rego➕PD1/PDL1⛔️
4️⃣Cabo➕Nivo
What other combinations are you excited about❓#CRCSM #HPBCSM
#WorldGI2020 @myESMO more discussions on 💡IDEA #clinicaltrials. What’d be of value would be integration of #ctDNA #liquidbiopsies 🩸🧬into the current algorithms of decision making. Often #ctDNA data is viewed in isolation. I see it more as an adjunct current paradigms #CRCSM.
❓ #WorldGI2020 @myESMO
I know we have had some discussions before @ASCO. How do you see the current 👇🏾#TNM classification changing ē novel markers #ctDNA #immunoscore ?stroma.
Esp. for ctDNA➕, do you see those pts as early stage+ like N1c(deposit) or are these truly stage4️⃣❓
I know we have had some discussions before @ASCO. How do you see the current 👇🏾#TNM classification changing ē novel markers #ctDNA #immunoscore ?stroma.
Esp. for ctDNA➕, do you see those pts as early stage+ like N1c(deposit) or are these truly stage4️⃣❓
👆🏾More on the ❓raised about where the TNM classification is going for #colorectalcancer #CRCSM. From #ctDNA integration to
TNM➖I🟥Immune
#HappeningNow @myESMO #WorldGI2020
Beyond TNM & clinical variables, is molecular status or immunoscore or MRD things you are doing now?
TNM➖I🟥Immune
#HappeningNow @myESMO #WorldGI2020
Beyond TNM & clinical variables, is molecular status or immunoscore or MRD things you are doing now?
#WorldGI2020 @myESMO #HappeningNow
Learning more beyond just
🟥MSI⬆️
#BRCA-ness
#DNARepair in #colorectalcancer
More data on #TMB from the TRIBE study. Here they used @carisls & cutoffs of 7️⃣ for the intermediate & 1️⃣6️⃣for high. Seems like more proximal tumors ē higher TML#CRCSM
Learning more beyond just
🟥MSI⬆️
#BRCA-ness
#DNARepair in #colorectalcancer
More data on #TMB from the TRIBE study. Here they used @carisls & cutoffs of 7️⃣ for the intermediate & 1️⃣6️⃣for high. Seems like more proximal tumors ē higher TML#CRCSM
#WorldGI2020 @myESMO👇🏾THIS‼️
The list of actionable aberrations in #colorectalcancer keeps increasing.
More importantly see:
#BRCA #DNAREPAIR 1️⃣4️⃣%🧬✅
We don’t talk much about that in #CRCSM. 💡need #clinicaltrials. Again need for NGS upfront ē 📈young-onset CRC. @OncoAlert
The list of actionable aberrations in #colorectalcancer keeps increasing.
More importantly see:
#BRCA #DNAREPAIR 1️⃣4️⃣%🧬✅
We don’t talk much about that in #CRCSM. 💡need #clinicaltrials. Again need for NGS upfront ē 📈young-onset CRC. @OncoAlert
...contd. #BRCA #DNAREpair #DDR
We had reported on this 2 yrs ago & also compiled all data. If you look at even germline studies, if UNSELECTED #CRCSM ~2% deleterious #BRCA. If we did a PANEL, we will find more. Like the 👆🏾study ē 1️⃣4️⃣%‼️#WorldGI2020 Hardtime finding a sponsor🙃
We had reported on this 2 yrs ago & also compiled all data. If you look at even germline studies, if UNSELECTED #CRCSM ~2% deleterious #BRCA. If we did a PANEL, we will find more. Like the 👆🏾study ē 1️⃣4️⃣%‼️#WorldGI2020 Hardtime finding a sponsor🙃
Can’t forget #CRCSM #POL-E hiding amidst MSS tumors. @agrothey discussing now @myESMO #WORLDGI2020 @OncoAlert
➕worth reiterating another case of MSI⬆️who was classified as pMMR/MSS picked up by NGS‼️
It may sound small numbers, #Immunotherapy’s impact not small for these pts.
➕worth reiterating another case of MSI⬆️who was classified as pMMR/MSS picked up by NGS‼️
It may sound small numbers, #Immunotherapy’s impact not small for these pts.
#WorldGI2020 @myESMO #HappeningNow @OncoAlert
Switching gears to
🟥#BRAFV600E
Updates to the doublet
🔴EGFR⛔️
🟠BRAF⛔️
Blockade in #colorectalcancer #CRCSM.
Interestingly ⬆️myalgias/arthralgias in doublet 🆚 triplet. Anyone else ē ideas. I have a pt >1 yr on this but struggling.
Switching gears to
🟥#BRAFV600E
Updates to the doublet
🔴EGFR⛔️
🟠BRAF⛔️
Blockade in #colorectalcancer #CRCSM.
Interestingly ⬆️myalgias/arthralgias in doublet 🆚 triplet. Anyone else ē ideas. I have a pt >1 yr on this but struggling.
#WorldGI2020 @myESMO FINALLY‼️
👇🏾the much awaited ANCHOR study.
🧬#BRAFV600E #CRCSM
🔴EGFR⛔️
🟠BRAF⛔️
🟢MEK⛔️
💦 plot with shrinkage in almost ALL patients. Even the ones who progressed were non-target or new lesions. @agrothey @OncoAlert
New SOC❓note: pts older/bad biology.
👇🏾the much awaited ANCHOR study.
🧬#BRAFV600E #CRCSM
🔴EGFR⛔️
🟠BRAF⛔️
🟢MEK⛔️
💦 plot with shrinkage in almost ALL patients. Even the ones who progressed were non-target or new lesions. @agrothey @OncoAlert
New SOC❓note: pts older/bad biology.
#WorldGI2020 @myESMO @OncoAlert
... contd. #CRCSM #BRAFV600E
PFS of BEACON & ANCHOR #clinicaltrials is similar. Resistance to the triplet blockade
🚂 ⛔️EGFR⛔️BRAF⛔️MEK
develops pretty much around the same time. How do you #SEQUENCE or 💡switch at molecular progression #ctDNA&♻️.
... contd. #CRCSM #BRAFV600E
PFS of BEACON & ANCHOR #clinicaltrials is similar. Resistance to the triplet blockade
🚂 ⛔️EGFR⛔️BRAF⛔️MEK
develops pretty much around the same time. How do you #SEQUENCE or 💡switch at molecular progression #ctDNA&♻️.
#WorldGI2020 @OncoAlert
... contd. #CRCSM #BRAFV600E
BEACON 🆚 ANCHOR
#clinicaltrials
🚂 ⛔️EGFR⛔️BRAF⛔️MEK
Very very similar.
@michael_overman presenting @myESMO
... contd. #CRCSM #BRAFV600E
BEACON 🆚 ANCHOR
#clinicaltrials
🚂 ⛔️EGFR⛔️BRAF⛔️MEK
Very very similar.
@michael_overman presenting @myESMO
#WorldGI2020 @myESMO @OncoAlert
#CRCSM #BRAFV600E
A lot of discussion about #CEA elevations at baseline 🆚 kinetics. Of note only 77% has an elevation.
I wanted to share/propose some💡. @agrothey @skopetz
Let’s look at the ratios. See our📝 .
19-9/CEA
jgo.amegroups.com/article/view/3…
#CRCSM #BRAFV600E
A lot of discussion about #CEA elevations at baseline 🆚 kinetics. Of note only 77% has an elevation.
I wanted to share/propose some💡. @agrothey @skopetz
Let’s look at the ratios. See our📝 .
19-9/CEA
jgo.amegroups.com/article/view/3…
#WorldGI2020 👇🏾THIS is what we need to figure out.
Who are these MSI⬆️patients who don’t respond to upfront #immunotherapy. 💡
🔴True progression
🟡?not true dMMR (confirm MSI/NGS)
🟢TMB
🟠?KRAS➕
🟣host immune system📉
Other thoughts/ideas❓
@myESMO @OncoAlert
#CRCSM
Who are these MSI⬆️patients who don’t respond to upfront #immunotherapy. 💡
🔴True progression
🟡?not true dMMR (confirm MSI/NGS)
🟢TMB
🟠?KRAS➕
🟣host immune system📉
Other thoughts/ideas❓
@myESMO @OncoAlert
#CRCSM
#WorldGI2020 Going back to who are these rare pts ē🧬FUSIONS.
🔶#NTRK
🔶#ALK
🔶#ROS-1
🔶#FGFR (ongoing trial by @KristenCiombor)
🔶RET (recent @AACR data @VivekSubbiah)
Data today from 👇🏾TRIBE-had 0️⃣❗️
💡?methods important(?RNA)➕fusions can be ACQUIRED 🩸🧬 #CRCSM @oncoalert
🔶#NTRK
🔶#ALK
🔶#ROS-1
🔶#FGFR (ongoing trial by @KristenCiombor)
🔶RET (recent @AACR data @VivekSubbiah)
Data today from 👇🏾TRIBE-had 0️⃣❗️
💡?methods important(?RNA)➕fusions can be ACQUIRED 🩸🧬 #CRCSM @oncoalert
@myESMO #WorldGI2020 data on REGO-NIVO study here is sobering. Definitely not the same ORR noted in the 🇯🇵 cohort study presented earlier. @OncoAlert #CRCSM
#WorldGI2020 @myESMO @OncoAlert
KRAS-G12C⛔️
AMG-510 💊
<sotoRAS🧬-ib>
CODEBreaK100 #ClinicalTrials
Exciting to see some drugs for our KRAS-mutant #cancer patients.
~12% of #LCSM
~2% of #CRCSM
Also 6 patients here had #PANCSMz
KRAS-G12C⛔️
AMG-510 💊
<sotoRAS🧬-ib>
CODEBreaK100 #ClinicalTrials
Exciting to see some drugs for our KRAS-mutant #cancer patients.
~12% of #LCSM
~2% of #CRCSM
Also 6 patients here had #PANCSMz
#WorldGI2020 @myESMO @OncoAlert 👇🏾THIS❗️
💡This is very intriguing.
Potentially one more way of targeting the 🧬#BRAFV600E #CRCSM
🔴BRAF⛔️
🟠MEK⛔️
➕
🟢#Immunotherapy
Note: most of these are MSS patients & paired tumor/blood analysis, ⬆️immune-pathways post RAF/MEK⛔️. #ctDNA🩸
💡This is very intriguing.
Potentially one more way of targeting the 🧬#BRAFV600E #CRCSM
🔴BRAF⛔️
🟠MEK⛔️
➕
🟢#Immunotherapy
Note: most of these are MSS patients & paired tumor/blood analysis, ⬆️immune-pathways post RAF/MEK⛔️. #ctDNA🩸
💡I wonder if one could consider #clinicaltrials ē switch strategies between 2 approaches. Although I’d do chemo+/-VEGF between targeted therapies.#BrafV600E
Chemo+VEGF⛔️
|
🚂⛔️EGFR⛔️RAF
|
♻️ Chemo+VEGF⛔️
|
🚂⛔️RAF⛔️MEK➕#Immunotherapy
|
♻️Chemo+VEGF⛔️
#CRCSM 💡 💭 #WorldGI2020
Chemo+VEGF⛔️
|
🚂⛔️EGFR⛔️RAF
|
♻️ Chemo+VEGF⛔️
|
🚂⛔️RAF⛔️MEK➕#Immunotherapy
|
♻️Chemo+VEGF⛔️
#CRCSM 💡 💭 #WorldGI2020
#WorldGI2020 @myESMO truly worth applauding the design and conduct of a surgical trial with perioperative systemic chemotherapy in patients with #ColorectalCancer ē resectable peritoneal metastases. So many moving targets. To accrue & capture all 📊👍🏽👏🏽. In practice systemic 1st.
#WorldGI2020 @myESMO @OncoAlert
I’ve always been very impressed ē the OVERALL SURVIVAL reported for patients ē #colorectalcancer on some of these trials. 👇🏾~4️⃣3️⃣ MONTHS for patients ē peritoneal metastases
Systemic➡️Cytoreductive surgery➕HIPEC
It’s more the CRS that’s worth➡️📈.
I’ve always been very impressed ē the OVERALL SURVIVAL reported for patients ē #colorectalcancer on some of these trials. 👇🏾~4️⃣3️⃣ MONTHS for patients ē peritoneal metastases
Systemic➡️Cytoreductive surgery➕HIPEC
It’s more the CRS that’s worth➡️📈.
#WorldGI2020 @myESMO let’s learn about #ctDNA #liquidbiopsies 🩸🧬.
👇🏾This is very 🆒.
#SHEDDING💦
Is dependent on where the #CRCSM metastases are.
1️⃣LIVER
2️⃣PERITONEAL
3️⃣LUNG
Lowest concordance for lung; goes📈ē size & # of mets.
Liver concordance is >90% regardless. @OncoAlert
👇🏾This is very 🆒.
#SHEDDING💦
Is dependent on where the #CRCSM metastases are.
1️⃣LIVER
2️⃣PERITONEAL
3️⃣LUNG
Lowest concordance for lung; goes📈ē size & # of mets.
Liver concordance is >90% regardless. @OncoAlert
#WorldGI2020 @myESMO @OncoAlert
👇🏾this I have a hard time believing.
I don’t think just on chemo+VEGF⛔️one can “CONVERT” #KRAS➕patients to wild-type. Acquisition post EGFR⛔️I get & makes sense. I have not seen this. On therapy shedding📉. It is not detectable ❌= conversion.
👇🏾this I have a hard time believing.
I don’t think just on chemo+VEGF⛔️one can “CONVERT” #KRAS➕patients to wild-type. Acquisition post EGFR⛔️I get & makes sense. I have not seen this. On therapy shedding📉. It is not detectable ❌= conversion.
#WorldGI2020 @myESMO @OncoAlert more 📊from #ctDNA #liquidbiopsies in the #MinimalResidualDisease setting from the Expanded Access.
>500 pts 700🩸samples.
👇🏾pertains to the #OLIGO-metastatic cohort of patients. Strikingly high numbers of #ctDNA➕📈. #clinicaltrials opportunity.
>500 pts 700🩸samples.
👇🏾pertains to the #OLIGO-metastatic cohort of patients. Strikingly high numbers of #ctDNA➕📈. #clinicaltrials opportunity.
Day4️⃣ #WorldGI2020 @myESMO let’s learn more about #ctDNA #liquidbiopsies 🩸🧬. Check out our 2 min📺🎞 on #CONCORDANCE #ctDNAInsights. 🙏 @OncoAlert.
1️⃣👇🏾This is very 🆒.💡
#SHEDDING💦🧬
📈in #CRCSM metastases varies ē site
1️⃣LIVER
2️⃣PERITONEAL
3️⃣LUNG
1️⃣👇🏾This is very 🆒.💡
#SHEDDING💦🧬
📈in #CRCSM metastases varies ē site
1️⃣LIVER
2️⃣PERITONEAL
3️⃣LUNG
#WorldGI2020 @myESMO @oncoalert
🧬#HER2🟩
Some of the challenges that are being discussed now can potentially in my opinion be overcome by using #ctDNA #liquidbiopsies in parallel at baseline & at progression. @YJanjigianMD showed some data & work by @DocCatenacci earlier. 🩸🧬
🧬#HER2🟩
Some of the challenges that are being discussed now can potentially in my opinion be overcome by using #ctDNA #liquidbiopsies in parallel at baseline & at progression. @YJanjigianMD showed some data & work by @DocCatenacci earlier. 🩸🧬
#WorldGI2020 @myESMO @oncoalert important to not forget about #rarecancers #RareDisease.
#cholangiocarcinoma also has the #BRAFV600E. Data on the ROAR🐯clinical trial already presented @ASCO @ASCO_pubs.
Didn’t need the same 🚂 ⛔️EGFR⛔️BRAF⛔️MEK
Dual inhibition sufficient.
#cholangiocarcinoma also has the #BRAFV600E. Data on the ROAR🐯clinical trial already presented @ASCO @ASCO_pubs.
Didn’t need the same 🚂 ⛔️EGFR⛔️BRAF⛔️MEK
Dual inhibition sufficient.
#WorldGI2020 @myESMO @oncoalert ...contd. discussion on #biomarkers in #cholangiocarcinoma
“TARGET-RICH” 🎯
What else would you add?💭
Some of the updates on 🟩HER2 ē the destiny & other agents ➕ 🟥BRAF would be 💡 to explore in @curecc. @WCGIC
“TARGET-RICH” 🎯
What else would you add?💭
Some of the updates on 🟩HER2 ē the destiny & other agents ➕ 🟥BRAF would be 💡 to explore in @curecc. @WCGIC
#WorldGI2020 @myESMO @oncoalert
I think this👇🏾slide is probably the 1st of many to come where expert discussants are commenting on the utility & integration into practice for #ctDNA #LiquidBiopsies.
🟢at diagnosis for #CRCSM
🟢at the time of EGFR⛔️re-challenge 🦗 #clinicaltrials
I think this👇🏾slide is probably the 1st of many to come where expert discussants are commenting on the utility & integration into practice for #ctDNA #LiquidBiopsies.
🟢at diagnosis for #CRCSM
🟢at the time of EGFR⛔️re-challenge 🦗 #clinicaltrials
#WorldGI2020 @myESMO @oncoalert contd.. more on biomarkers in #ESOCSM #STCSM
🟢HER2
🔵MMR/MSI
🟣PD-L1
⚪️EBV
⚫️?TMB
🔜BRCA/DDR #clinicaltrials
Of note ⚪️EBV more in gastric than GEJ/Esophageal. Mutually exclusive to 🔵dMMR/MSI⬆️. 2-4% in most series. 💭 @GillSharlene add #TMB?
🟢HER2
🔵MMR/MSI
🟣PD-L1
⚪️EBV
⚫️?TMB
🔜BRCA/DDR #clinicaltrials
Of note ⚪️EBV more in gastric than GEJ/Esophageal. Mutually exclusive to 🔵dMMR/MSI⬆️. 2-4% in most series. 💭 @GillSharlene add #TMB?
#WorldGI2020 @myESMO @oncoalert great summary slide looking at ❓ #immunotherapy #biomakers in #HepatocellularCarcinoma across various studies. @WCGIC
#WorldGI2020 @myESMO @oncoalert what’s the most recent consensus on #Immunotherapy & #COVID19.
While theoretical concerns, I thought that the data so far argues against any detriment. @WCGIC maybe #lcsm⬆️.
Thoughts @tmprowell @agrothey @marklewismd @weoncologists @NicoleKuderer
While theoretical concerns, I thought that the data so far argues against any detriment. @WCGIC maybe #lcsm⬆️.
Thoughts @tmprowell @agrothey @marklewismd @weoncologists @NicoleKuderer
#WorldGI2020 @myESMO @oncoalert examples of consensus statements of #cancercare @myESMO to 📉risk of exposure to #COVID19. #PANCSM #telehealth #telemedicine 📺
With the decrease in surgeries, there was more leaning to do neoadjuvant approaches & shorter courses of XRT.
With the decrease in surgeries, there was more leaning to do neoadjuvant approaches & shorter courses of XRT.
Day4️⃣ #WorldGI2020 @myESMO let’s learn more about #ctDNA #liquidbiopsies 🩸🧬. Check out our 2 min📺🎞 on #ctDNAInsights from @WCGIC. 🙏 @OncoAlert.
This is video 2️⃣of5️⃣.
Discussion of #MinimalResidualDisease #MRD - 📊 in OLIGO-metastatic #CRCSM.
This is video 2️⃣of5️⃣.
Discussion of #MinimalResidualDisease #MRD - 📊 in OLIGO-metastatic #CRCSM.
#WorldGI2020 @myESMO @oncoalert switching gears to #rectalcancer - one subset that merits a different systemic approach is the MSI⬆️group of rectal cancers.
Not so much the ☢️part but the chemo actually patients can progress. @sloan_kettering @FoxtrotStudy #immunotherapy
Not so much the ☢️part but the chemo actually patients can progress. @sloan_kettering @FoxtrotStudy #immunotherapy
#WorldGI2020 @myESMO @oncoalert Response% in RAPIDO📖 #rectalcancer are probably one of the most discussed results. Has your institution changed practice? Our XRT oncology colleagues have been very open to it.
🔑 👇🏾takeaway “The good get a better outcome.”
?Role for #ctDNA. TNT
🔑 👇🏾takeaway “The good get a better outcome.”
?Role for #ctDNA. TNT
#WorldGI2020 @myESMO @oncoalert one 🔑 recurring theme that makes the case for TNT stronger is this👇🏾.
Post-operative compliance & rates of completion of chemotherapy are a lot lower. And that’s not just for rectal cancer, similar themes in #PANCSM arguing in favor of TNT💡.
Post-operative compliance & rates of completion of chemotherapy are a lot lower. And that’s not just for rectal cancer, similar themes in #PANCSM arguing in favor of TNT💡.
#WorldGI2020 @myESMO @oncoalert more on #rectalcancer - & now #immunotherapy #clinicaltrials
the VOLTAGE⚡️study👇🏾
1️⃣ChemoXRT 50.4Gy➕CAPE
|
2️⃣5 cycles of PD1⛔️
|
3️⃣Surgery
pCR
30%-MSS
60%-MSI⬆️
Is the @NRGonc pembro arm in TNT read out? I’m not sure. @OsamaRahma2 @TGeorgeMD
the VOLTAGE⚡️study👇🏾
1️⃣ChemoXRT 50.4Gy➕CAPE
|
2️⃣5 cycles of PD1⛔️
|
3️⃣Surgery
pCR
30%-MSS
60%-MSI⬆️
Is the @NRGonc pembro arm in TNT read out? I’m not sure. @OsamaRahma2 @TGeorgeMD
Day4️⃣ #WorldGI2020 @myESMO let’s learn more about #ctDNA #liquidbiopsies 🩸🧬. 👇🏾Check out our 2 min📺🎞 on #ctDNAInsights from @WCGIC. 🙏 @OncoAlert.
This is video 3️⃣of5️⃣.
Discussion of abstracts & presentations relating to serial #ctDNA🩸 monitoring.
This is video 3️⃣of5️⃣.
Discussion of abstracts & presentations relating to serial #ctDNA🩸 monitoring.
Day4️⃣ #WorldGI2020 @myESMO let’s learn more about #ctDNA #liquidbiopsies 🩸🧬. 👇🏾Check out our 2 min📺🎞 on #ctDNAInsights from @WCGIC. 🙏 @OncoAlert.
This is video 4️⃣of5️⃣.
More on ASSAY-specific caveats & interpretation. @skopetz
This is video 4️⃣of5️⃣.
More on ASSAY-specific caveats & interpretation. @skopetz
Day4️⃣ #WorldGI2020 @myESMO let’s learn more about #ctDNA #liquidbiopsies 🩸🧬. 👇🏾Check out our 2 min📺🎞 on #ctDNAInsights from @WCGIC. 🙏 @OncoAlert.
...contd. This is video 5️⃣of5️⃣.
More on ASSAY-specific caveats & interpretation. @skopetz
...contd. This is video 5️⃣of5️⃣.
More on ASSAY-specific caveats & interpretation. @skopetz
🤖 @ThreadReaderApp #WorldGI2020 Unroll 🧵
